LIVN

+ Watchlist + Portfolio

LivaNova PLC

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $74.70
52-Week Range: $48.82 – $85.76
Market Cap: $4.14B
P/E (TTM): 22.21
EPS (TTM): 3.38
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 3.12
PEG Ratio: 0.93
Return on Equity: 15.40%
Return on Assets: 5.04%
Gross Margin: 67.74%
Operating Margin: 13.54%
Profit Margin: 12.81%
Current Ratio: 1.45
Debt/Equity: 0.27
Total Debt: $351.95M
Free Cash Flow: $59.87M
Revenue Growth: 10.80%
Earnings Growth: 287.80%
Enterprise Value: $3.97B

LIVN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.02B	$1.15B	$1.25B	$1.39B
Cost of Revenue	$314.58M	$397.73M	$399.95M	$448.18M
Gross Profit	$707.23M	$755.82M	$853.48M	$939.87M
Research & Development	$155.81M	$193.82M	$182.51M	$185.76M
Selling, General & Admin	$469.24M	$502.70M	$508.88M	$548.81M
Operating Expenses	$654.58M	$734.34M	$724.43M	$740.48M
Operating Income	$52.64M	$21.48M	$129.05M	$199.39M
EBITDA	$30.90M	$38.48M	$202.52M	-$111.86M
Pretax Income	-$75.14M	-$81.23M	$88.31M	-$220.78M
Income Tax	$11.05M	-$98.88M	$25.06M	$21.64M
Net Income	-$86.25M	$17.55M	$63.23M	-$242.47M
Diluted EPS	-1.61	0.32	1.16	-4.45
Diluted Shares	53.50M	54.20M	54.60M	54.50M

LIVN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$214.17M	$266.50M	$428.86M	$635.55M
Receivables	$214.82M	$235.22M	$223.70M	$264.59M
Inventory	$129.38M	$147.89M	$147.57M	$164.70M
Current Assets	$886.14M	$988.16M	$1.13B	$1.10B
Total Assets	$2.29B	$2.43B	$2.51B	$2.61B
Current Liabilities	$297.40M	$334.98M	$392.13M	$808.07M
Long-Term Debt	$518.07M	$568.54M	$549.62M	$345.19M
Total Debt	$580.43M	$640.40M	$676.77M	$433.77M
Total Liabilities	$1.09B	$1.15B	$1.19B	$1.41B
Retained Earnings	-$984.03M	-$966.48M	-$903.25M	-$1.15B
Shareholders' Equity	$1.21B	$1.28B	$1.32B	$1.20B
Working Capital	$588.74M	$653.17M	$735.06M	$293.54M
Net Debt	$327.33M	$320.15M	$198.77M	—

LIVN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$69.92M	$74.91M	$183.04M	$254.34M
Capital Expenditure	-$26.52M	-$34.98M	-$47.11M	-$81.05M
Free Cash Flow	$43.40M	$39.93M	$135.93M	$173.29M
Depreciation & Amortisation	$57.80M	$60.86M	$51.14M	$59.63M
Stock-Based Compensation	$44.81M	$36.35M	$33.93M	$36.29M
Investing Cash Flow	-$38.41M	-$40.33M	-$48.16M	-$72.91M
Financing Cash Flow	$280.13M	$21.48M	$18.55M	-$285.66M
Share Repurchases	-$8.67M	-$7.50M	-$8.44M	—
Net Change in Cash	$311.64M	$56.07M	$153.43M	-$104.23M

LIVN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$316.86M	$352.52M	$357.75M	$360.92M	$362.26M	$390.59M
Cost of Revenue	$100.60M	$113.54M	$112.90M	$121.15M	$118.51M	$116.92M
Gross Profit	$216.25M	$238.99M	$244.85M	$239.77M	$243.75M	$273.67M
Research & Development	$37.88M	$47.19M	$48.58M	$52.12M	$58.70M	$53.66M
Selling, General & Admin	$129.15M	$137.78M	$138.52M	$143.37M	$143.57M	$158.13M
Operating Expenses	$167.64M	$184.81M	$190.84M	$197.19M	$202.28M	$224.19M
Operating Income	$48.62M	$54.18M	$54.01M	$42.58M	$41.47M	$49.48M
EBITDA	-$285.69M	$63.29M	$59.99M	$53.20M	$51.37M	$43.85M
Pretax Income	-$315.65M	$33.32M	$33.91M	$27.63M	$27.48M	$18.48M
Income Tax	$11.66M	$6.15M	$7.11M	-$3.28M	$4.34M	-$90.20M
Net Income	-$327.32M	$27.16M	$26.78M	$30.91M	$22.29M	$108.57M
Diluted EPS	-6.01	0.50	0.49	0.56	0.40	1.93
Diluted Shares	54.40M	54.70M	55.20M	55.50M	55.90M	56.30M

LIVN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$738.44M	$593.64M	$646.08M	$635.55M	$539.71M	$516.62M
Receivables	$231.42M	$252.98M	$239.11M	$264.59M	$270.55M	$274.17M
Inventory	$154.02M	$165.35M	$167.54M	$164.70M	$165.50M	$172.61M
Current Assets	$1.17B	$1.07B	$1.10B	$1.10B	$1.01B	$1.03B
Total Assets	$2.56B	$2.51B	$2.56B	$2.61B	$2.52B	$2.64B
Current Liabilities	$741.57M	$827.10M	$827.59M	$808.07M	$762.48M	$707.00M
Long-Term Debt	$549.22M	$348.49M	$349.03M	$345.19M	$285.16M	$289.91M
Total Debt	$677.85M	$482.78M	$486.55M	$433.77M	$343.44M	$351.95M
Total Liabilities	$1.52B	$1.38B	$1.40B	$1.41B	$1.31B	$1.32B
Retained Earnings	-$1.23B	-$1.20B	-$1.18B	-$1.15B	-$1.12B	-$1.01B
Shareholders' Equity	$1.03B	$1.12B	$1.16B	$1.20B	$1.21B	$1.33B
Working Capital	$429.58M	$239.04M	$269.56M	$293.54M	$251.76M	$318.04M

LIVN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$23.97M	$62.92M	$85.06M	$82.40M	$15.22M	$66.59M
Capital Expenditure	-$10.79M	-$15.15M	-$22.88M	-$32.23M	-$14.29M	-$31.55M
Free Cash Flow	$13.18M	$47.77M	$62.18M	$50.16M	$926.00K	$35.04M
Depreciation & Amortisation	$14.67M	$15.04M	$15.21M	$14.71M	$15.60M	$18.20M
Stock-Based Compensation	$7.78M	$9.17M	$9.95M	$9.39M	$8.27M	$16.88M
Investing Cash Flow	-$10.63M	-$8.97M	-$23.06M	-$30.26M	-$14.58M	-$31.92M
Financing Cash Flow	-$4.42M	-$208.98M	-$9.37M	-$62.88M	-$94.25M	-$56.45M
Net Change in Cash	$8.92M	-$155.03M	$52.63M	-$10.75M	-$93.61M	-$21.78M

Market Snapshot

About

LivaNova PLC is a global medical technology company focused on cardiovascular and neuromodulation solutions. The company develops and manufactures products for cardiac surgery, including heart-lung machines and oxygenators, as well as neuromodulation devices for epilepsy and treatment-resistant depression. LivaNova's product portfolio spans cardiac rhythm management, cardiac surgery, and advanced circulatory support technologies. The company serves healthcare providers worldwide with innovative medical devices and patient monitoring systems.